Zantac recall
Based on information received to date and correspondence with regulatory authorities, GSK has made the decision to initiate a voluntary recall (pharmacy/retail level recall) of Zantac products in all markets as a precautionary action.
GSK Respiratory
See the products offers across our Elipta portfolio and how these can support your patients with the treatment of asthma and COPD.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
Trade marks are owned by or licensed to the GSK group of companies.